News & Updates

Treatment with the investigational oral orexin receptor 2–selective agonist oveporexton appears to yield improvements in wakefulness, sleepiness, and cataplexy in individuals with narcolepsy type 1, according to the results of a phase II study.

Fremanezumab appears to provide a two-for-one benefit in patients with migraine and comorbid depressive disorder, with data from the UNITE study showing that the drug helped reduce migraine days and lift mood.

Treatment with targeted-release budesonide formulation preserves kidney function and reduces proteinuria in patients with IgA nephropathy (IgAN) independent of baseline eGFR, and this benefit is seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period, according to a subanalysis of the phase III NeflgArd study presented at the ERA annual meeting.

Treatment with steady-state, low-dose morphine does not appear to improve sleep efficiency, sleep-disordered breathing frequency, or next-day alertness but may rather result in hypoventilation during sleep in chronic obstructive pulmonary disease (COPD) patients with chronic breathlessness, according to the results of a randomized, double-anonymized, crossover trial.

Maintenance treatment with vedolizumab proved safe and effective in paediatric inflammatory bowel disease (IBD), with long-term remission achieved more frequently in children with ulcerative colitis (UC) than in those with Crohn’s disease (CD), according to the final 3-year data from the VEDOKIDS study.

Treatment with the combination of zanidatamab plus palbociclib and fulvestrant is safe and demonstrates promising antitumour activity in patients with HR-positive, HER2-positive advanced or metastatic breast cancer, according to a phase IIa study.

Both drotaverine and peppermint oil are safe and help alleviate abdominal pain in children whose pain cannot be attributed to a specific medical condition, with neither treatment demonstrating clear superiority over the other, according to the results of a single-blind, randomized controlled trial.

A nurse-led mobile health (mHealth) intervention that utilizes basic phones improves blood pressure (BP) control among stroke survivors in Ghana, as shown in the phase III PINGS-2 trial.